Lake Street Initiates Coverage On C4 Therapeutics with Buy Rating, Announces Price Target of $11

Benzinga · 4d ago
Lake Street analyst Chad Messer initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating and announces Price Target of $11.